Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.22.36 (
caspase-1
)
6,285
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Interleukin-1 beta (IL-1 beta)-converting enzyme (
ICE
,
caspase-1
) processes the IL-1 beta precursor to mature inflammatory cytokine IL-1 beta.
ICE
has been identified as a unique cysteine protease, which cleaves Asp-X bonds, shows resistance to E-64 (an inhibitor of most cysteine proteases) and has a primary structure that is homologous to CED-3, a protein required for apoptosis (programmed cell death) in the nematode Caenorhabditis elegans, and to mammalian cysteine proteases that initiate and execute apoptosis, e.g., apopain/CPP32/caspase-3. The inhibitors of the
ICE
/CED-3 family or caspases, as they are called recently, may constitute therapeutic agents for amelioration of inflammatory and apoptosis-associated diseases. The most efficient
ICE
inhibitors are peptide aldehydes and peptidyl chloro or (acyloxy)methanes. A recent study revealed that both D- and L-Asp are accepted by
ICE
at the P1 of such inhibitors, and the peptidyl (acyloxy)
methane
analogues having the beta-homo-aspartyl residue [-NH-CH(CH2COOH)-CH2CO-] are inactive. These findings we reexamined in terms of two issues. (a)
ICE
's resistance to E-64. Since it was thought to be caused by the enzyme's unique substrate specificity, we prepared substrate-based analogues, which were not inhibitory suggesting significant structural difference between the active centers of
ICE
and papain-like enzymes. (b) Tolerance for D-stereochemistry at the P1 of these inhibitors. In view of the mechanism of cysteine protease inhibition by peptidyl X-methanes, we thought that this phenomenon should be a general characteristic of cysteine proteases and the hAsp-containing analogues should behave as reversible inhibitors. Here, we analyzed the inhibition of
ICE
and apopain in comparison with that of papain, thrombin, and trypsin by peptide L/D-alpha-aldehydes and their L-beta-homo-aldehyde [-NH-CH(R)-CH2-CHO] analogues. The following results were found. (1) The peptidyl L-beta-homo-aspartals are potent inhibitors for caspases. (2) The L-beta-homo analogues of peptide aldehyde inhibitors designed for other proteases are not inhibitory. (3) Unlike trypsin and thrombin (serine proteases), papain (cysteine protease) shows tolerance for D-stereochemistry at the P1 site of peptide aldehydes in proportion to the lability of the alpha-hydrogen of the P1-D-residue. The complete tolerance of
ICE
for P1-D-Asp may arise from this residue's high tendency to epimerization. (4) Reaction of cysteine proteases with peptide aldehyde or peptidyl X-
methane
inhibitors containing P1-D-residues may include alpha-proton abstraction followed by asymmetric induction leading to P1-L-residue-containing products.
...
PMID:Peptidyl beta-homo-aspartals (3-amino-4-carboxybutyraldehydes): new specific inhibitors of caspases. 1038 Mar 58
Mahanine, a carbazole alkaloid occurs in the edible part of Micromelum minutum, Murraya koenigii and related species has been found to induce apoptosis in human myeloid cancer cell (HL-60). Concentration of 10 microM mahanine caused a complete inhibition of cell proliferation and the induction of apoptosis in a time dependent manner. Mahanine-induced cell death was characterized with the changes in nuclear morphology, DNA fragmentation, activation of caspase like activities, poly(ADP-ribose) polymerase cleavage, release of cytochrome c into cytosol and stimulation of reactive oxygen species generation. The cell death was completely prevented by a pancaspase inhibitor benzyloxycarbonyl-L-aspart-1-yl-[(2,6-dichlorobenzoyl)oxy]
methane
(Z-Asp-CH(2)-DCB). Mahanine activated various caspases such as caspase-3, -6, -8 and -9 (like) activities but not
caspase-1
like activity. More than 70% cell survival was observed in the presence of a caspase-3 inhibitor. In addition, co-treatment of cyclosporin A markedly increased the survival of mahanine-treated HL-60 cells. Flow cytometric analysis revealed that mahanine decreased the mitochondrial membrane potential of intact cells, and disrupted cell cycle progression by increasing the number of cells in sub-diploid region, concomitantly with the decrease of cells in diploid phases, particularly at late hours of apoptosis. The overall results suggest that mahanine down regulates cell survival factors by activation of caspase-3 through mitochondrial dependent pathway, and disrupts cell cycle progression.
...
PMID:Mechanism of mahanine-induced apoptosis in human leukemia cells (HL-60). 1466 27
On-site production of hydrogen and carbon nanofibers by thermocatalytic decomposition (TCD) of mineral oil waste (MWO) is analyzed. An experimental study carried out at lab scale to estimate the yields that can be expected from TCD of the MWO collected in the Aragon area is presented. Based on these results, mass and energy balance have been carried out to have a preliminary estimation on the products that could be obtained by processing the 10 000 tonnes/year of MWO that can be collected in the Aragon region. The process would consist of four steps: (1) drying, (2) vaporization, (3) primary decomposition, and (4) catalytic decomposition. After drying and vaporization, MWO is converted in step 3 into fuel grade carbon and a gas mixture that mainly contains hydrogen and
methane
.
Methane
is partially converted in step 4 into hydrogen and a carbon material that contains carbon nanofibers which could be used to manufacture utilities with high added value. The 10 000 tonnes/year of MWO would yield 705 t/y of H2, 4962 t/y of fuel grade carbon, and 1016 t/y of pure carbon. The mixture obtained (71% H2: 23%
CH4
) could be used as a hydrogen source to obtain pure hydrogen or hydrogen-natural gas mixtures to fuel a captive fleet of public urban vehicles powered by fuel cells or dedicated
ICE
, respectively.
...
PMID:On-site production of hydrogen from mineral waste oils by thermocatalytic decomposition: an Aragon case study. 1619 Feb 51